STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
Enjoy, and see you soon.… Takeda reported that its narcolepsy pill, the first treatment to target the underlying cause of the rare sleep disorder, is now available in the U.S.
Key points
- Pfizer will no longer sell its hormone replacement therapy Premarin, which has been available as a vaginal cream and three strengths of oral tablets, in Canada following an internal review, Reuters reports.
- Premarin vaginal cream, used to treat symptoms of menopause, has been in shortage in Canada since June and no further batches will be supplied.
- Demand for hormone replacement therapy has been rising, particularly in the U.S., where prescriptions have increased after the U.S.
We plan to tidy the Pharmalot grounds, catch up on our reading, promenade with the official mascots, and of course, hold a listening party with Mrs.
The DEA has classified Orzeyful as a Schedule IV controlled substance, a category considered to have a low potential for abuse and dependence.
Additional details
- Continue to STAT+ to read the full story….
- Some other hormone therapy products to treat menopause symptoms are also facing supply constraints in Canada.
- Drug Enforcement Administration removed the final regulatory hurdle for its rollout, Reuters notes.
- Holidays are approaching so perhaps this an opportunity to go shopping and boost the economy.
- list price has been set at $16,500 per 60-tablet bottle, across all strengths.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.